5 March 2021 - Yescarta is the first CAR T-cell therapy approved for indolent follicular lymphoma; approval marks the third ...
3 March 2021 - Blueprint Medicines today announced that the EMA has validated the company's type II variation marketing authorisation application ...
3 March 2021 - BLA submitted with FDA’s breakthrough therapy designation. ...
3 March 2021 - Approval is based on CROWN trial, which showed a 72% reduction in risk of progression or ...
4 March 2021 - The UK’s NICE has not recommended Kyowa Kirin’s Poteligeo for the treatment of adults living with ...
3 March 2021 - On Target Laboratories today announced that the U.S. FDA has accepted its new drug application for priority ...
3 March 2021 - Oblato announces that the FDA granted fast track designation of OKN-007, the proprietary drug for diffuse intrinsic ...
2 March 2021 - The drug-buying agency was placed under an independent review today after the Prime Minister said she ...
2 March 2021 - Approval is based on the Phase 3 ASPEN trial of Brukinsa compared to ibrutinib. ...
1 March 2021 - Merck today announced the company is voluntarily withdrawing the U.S. indication for Keytruda (pembrolizumab) for the treatment ...
1 March 2021 - Agios Pharmaceuticals today announced that it has submitted a Supplemental new drug application to the U.S. FDA ...
1 March 2021 - Athenex today announced that the U.S. FDA has issued a complete response letter for the company’s ...
26 February 2021 - Today the FDA granted accelerated approval to melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with dexamethasone ...
26 February 2021 - Incyte today announced the validation of the Company’s marketing authorisation application for retifanlimab, an intravenous PD-1 ...
26 February 2021 - GlaxoSmithKline today announced the CHMP of the EMA has adopted a positive opinion recommending dostarlimab, an anti-programmed ...